99.54 percent subscription rate in Brighter's rights issue – corresponding to SEK 191 million

The outcome of Brighter's rights issue, announced on November 18, 2019, has now been determined. The subscription rate amounts to 99.54% of the offered shares, which strengthens the company with approximately SEK 191 million. The issue costs amount to only about SEK 1 million, corresponding to about 0.5% of the issue amount.

“Brighter has successfully completed a rights issue that strengthens the company financially and provides resources for wide-scale commercialization of Actiste. The rights issue was designed to enable as many shareholders as possible to participate and subscribe for shares, as well as to execute a very cost-efficient capital raise. Thanks to the great interest to participate, Brighter now has the financial resources to move forward in accordance with our plan,” says Henrik Norström, Brighter's CEO.

95 673 156 new shares are issued in this rights issue. The total number of shares in the company after the issue amounts to 191 784 360. The share capital increases by SEK 4 783 657,80 to a total of SEK 9 589 218,00.

Trading with BTA will take place on Nasdaq First North Growth Market until the conversion of BTA into ordinary shares, which is expected to take place week 5, 2020.

For further information, please contact:

Ann Zetterberg, CFO
Phone: +46 708 37 21 23
Email: ann.zetterberg@brighter.se

Henrik Norström, CEO 
Phone: +46 733 40 30 45
Email: henrik.norstrom@brighter.se

About Brighter AB (publ)

Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. https://brighter.se/

The Company's shares are listed on Nasdaq First North Growth Market/BRIG. Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se.

This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 17:00 CET on January 14, 2020.

About Us

Brighter is a Swedish health-tech company with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. https://brighter.se/ The Company's shares are listed on Nasdaq First North Growth Market/BRIG. Brighter’s Certified Adviser is Eminova Fondkommission AB +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se

Subscribe

Documents & Links